Skip to main
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics Inc. has demonstrated a strong financial performance, with Q3 2025 revenue increasing by 63.3% year-over-year to $27.3 million, significantly surpassing previous estimates by $3.8 million. The company's management has raised revenue projections for FY25 by over $6 million to a target exceeding $96.5 million, reflecting confidence in ongoing growth. Furthermore, the substantial rise in new patient starts, particularly from conversions of multiple daily injection patients, coupled with a higher mix of higher-margin sales through the pharmacy channel, underpins a positive outlook for robust revenue growth into 2026 and beyond.

Bears say

Beta Bionics Inc faces significant challenges that negatively impact its financial outlook, including the potential failure to gain meaningful market share for its iLet product amid competitive pressures and difficulties in securing sustained penetration in the pharmacy channel. The company's EBITDA loss of $12.2 million exceeds prior estimates, and slower than anticipated adoption due to the absence of FDA label expansion further complicates revenue generation. Additionally, prospective regulatory changes in Medicare reimbursement and the need for additional capital could lead to shareholder dilution, compounding the financial risks the company faces.

BBNX has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 9 analysts, BBNX has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.